Role of progestins with partial antiandrogenic effects

  title={Role of progestins with partial antiandrogenic effects},
  author={R{\'e}gine Sitruk-Ware and Friedrich Husmann and J. J. H. Thijssen and S. O. Skouby and Franca Fruzzetti and Jurgen P. Hanker and Johannes C. Huber and Ren{\'e} A Druckmann},
  pages={238 - 254}
An experts' meeting on the ‘Role of progestins with partial antiandrogenic effects’ was held in Berlin from January 19 to 22, 2001. The meeting was chaired by Dr R. Sitruk-Ware (New York, USA) and participants included Ms F. Fruzzetti (Pisa, Italy), J. Hanker (Trier, Germany), J. Huber (Vienna, Austria), F. Husmann (Bad Sassendorf, Germany), S. O. Skouby (Copenhagen, Denmark), J. H. H. Thijssen (Utrecht, The Netherlands), and R. Druckmann (Nice, France). The present paper reports the… 

Progestins in HRT: sufferance or desire?

Estrogen, medroxyprogesterone acetate, endothelial function, and biomarkers of cardiovascular risk in young women.

It is suggested that acute MPA administration negates the beneficial effects of estradiol on endothelium-dependent vasodilation in young women and that the addition of MPA may counteract the effect of est radiol on endothelin-1.

The effect of different progestogens on sleep in postmenopausal women: a randomized trial

Sleep quality of peri-postmenopausal women with insomnia improved dramatically after the first month of hormonal treatment, and women in the micronized progesterone group had fewer overall side effects than those in the dydrogesterone group.

Differential effects of various progestogens on metabolic risk factors for breast cancer

While most biological and epidemiological findings suggest that natural progesterone does not augment breast cancer risk, available data show an increased risk with synthetic progestins – with the possible exception of progester one-derived dydrogesterone.

The effect of non‐oral hormonal contraceptives on hypertension and blood pressure: A systematic review and meta‐analysis

A lower incidence of hypertension was observed with injectable contraceptive use compared to non‐hormonal contraceptive and OC use, although it was unclear if this was statistically significant.

Ligand Binding Induces Agonistic-Like Conformational Adaptations in Helix 12 of Progesterone Receptor Ligand Binding Domain

The results, therefore, explain the partial agonism of the SPRM, which could induce weak agonistic effects in PR and it is found that co-repressor peptides could be stably associated with the LBD and stabilize the L BD in a “semi-open” state for helix 12.

Differential effects of progestogens on HIV-1 replication and host gene expression in primary PBMCs and cervical tissue explants

This study presents a meta-analysis showing that MPA, unlike NET, P4 and LNG, regulates immunomodulatory gene expression via the GR and increases HIV-1 replication in the majority of primary human PBMCS.

Differenzierter Einsatz von Gestagenen in der Peri- und Postmenopause

Therapeutic options for treatment with sexual steroids in the perimenopausal transition and afterwards have multiplied in the last decades and there are numerous different preparations and medications for choosing the optimal therapy for each patient.



Antiandrogenic progestins for treatment of signs of androgenisation and hormonal contraception.

  • A. Schindler
  • Medicine, Biology
    European journal of obstetrics, gynecology, and reproductive biology
  • 2004

The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea.

EE/DRSP has been shown to be as effective for treating mild-to-moderate acne as a preparation containing EE/CPA, and this new preparation may provide useful hormone therapy for women with androgen-dependent disorders who also require contraception.

Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties.

  • A. Rübig
  • Biology, Medicine
    Climacteric : the journal of the International Menopause Society
  • 2003
Phase III studies with E2/DRSP show that DRSP does not antagonize the well-documented reductions of blood pressure associated with E1; rather, small DRSP dose-related reductions in systolic and diastolic blood pressures were observed, which should be beneficial for recipients, especially those who are mildly hypertensive.

The role of antiandrogens in hormone replacement therapy.

  • H. Schneider
  • Biology, Medicine
    Climacteric : the journal of the International Menopause Society
  • 2000
Continuous combined HRT with dienogest may come to be regarded as the HRT of choice in postmenopausal patients with mood defects and has specific indications with respect to preserving metabolic estrogenicity, specific antiandrogenic effects and specific effects on vigilance and mood disorders.

The pharmacological profile of a novel norpregnance progestin (trimegestone).

Results show trimegestone to have a favorable pharmacological profile with potent progestomimetic activity, and to be not associated with any unwanted pharmacological effects.

Progestogens in hormonal replacement therapy: new molecules, risks, and benefits

Complying with the classic contraindications of HRT and selecting molecules devoid of estrogenic, androgenic, or glucocorticoid effect should allow a larger use of the progestins without any major drawback.

Trimegestone: expanding therapeutic choices for the treatment of the menopause

The lipoprotein profile measured at baseline, 3 and 6 months during the dose ranging study confirmed the fact that trimegestone, irrespective of the dose, did not negate the beneficial effects of oestrogen on lipids.

Climodien® (estradiol valerate 2 mg plus dienogest 2 mg) is safe and effective in the treatment of postmenopausal complaints

Continuous combined estrogen-progestin therapy with Climodien is effective, safe and well tolerated in postmenopausal women, with a profile and incidence of adverse events consistent with those of existing HRT preparations.